osimertinib
astrazeneca
['lung', 'adaura', 'osimertinib']
5. at #asco23, the 5-year os rate was announced: 85% with osimertinib vs 73% with placebo for stage ii iiia disease patients. major strides in #lungcancerresearch from adaura! 
🫁Pneumo-Onco🩺 Chef de Pôle de Méd à Orientation Onco 🏥 @CHToulonLaSeyne 🔬Conseil Scientifique @IFCTLung / Pdte du 3C VarOuest 👉🏼#HopitalPublic #LungCancer